Device type · KFF
Assay, Heparin
Last checked: Nov 20, 2026Source: openFDAMethods & limitations
Product code
KFF
Hematology
Device class
Class II
FDA decisions since 2015
3
510(k), De Novo and PMA
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
How FDA classifies it
- Device type
- Assay, Heparin
- Product code
- KFF
- Device class
- Class II
- Review panel
- Hematology
- Regulation
- 21 CFR 864.7525
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for KFF
Latest FDA decisions
- STA® - Liquid Anti-Xa510(k)
K260214 · Decided Sep 24, 2026 · 244 days after receipt
Device type: Assay, Heparin (KFF) · Laboratory Medicine & Pathology
- HemosIL Liquid Anti-Xa510(k)
K213464 · Decided Oct 4, 2022 · 341 days after receipt
Device type: Assay, Heparin (KFF) · Laboratory Medicine & Pathology
Siemens Healthcare Diagnostics Prodcts GmbH
K162540 · Decided Aug 22, 2017 · 344 days after receipt
Device type: Assay, Heparin (KFF) · Laboratory Medicine & Pathology
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 0 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 0 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 1 | 0 | 0 | 0 |
| Sep 25 | 6 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 0 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 0 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 0 | 0 | 0 | 0 |
| Oct 26 | 0 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
No manufacturers to rank.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
No device problems coded.
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
No patient problems coded.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2474-2025 · Started Jul 21, 2025 · Posted by FDA Aug 28, 2025
Reason given: Potential for contamination of STA-LIQUID ANTI-Xa by Stago Fibrinogen reagents in UFH and LMWH applications.
Cause as FDA categorized it: Mixed-up of materials/components
Z-2475-2025 · Started Jul 21, 2025 · Posted by FDA Aug 28, 2025
Reason given: Potential for contamination of STA-LIQUID ANTI-Xa by Stago Fibrinogen reagents in UFH and LMWH applications.
Cause as FDA categorized it: Mixed-up of materials/components
- HemosIL LMW Heparin Controls; Part Number: 0020300200;Open, Classified
Z-2323-2025 · Started Feb 3, 2025 · Posted by FDA Aug 13, 2025
Reason given: Multiple complaints indicating lower than expected quality control (QC) results and in some instances QC recovery below the lower limit of the package insert acceptance range when testing is performed with HemosIL Liquid Anti-Xa and HemosIL Heparin Calibrator. In some complaints, failure to pass QC resulted in patient...
Cause as FDA categorized it: Process control
9 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.